Skip to main content
          Skip to FDA Search
          Skip to in this section menu
          Skip to footer links


U.S. flagAn official website of the United States government

					Here’s how you know
          			Dot gov**The .gov means it’s official.**Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you're on a federal government site.
							      SSL**The site is secure.** The **https://** ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely. 
			U.S. Food and Drug Administration
				
        Search
            Menu
							
						Search FDA
									
									Submit search 
		Featured
							Contact FDA
	                FDA Guidance Documents
	                Recalls, Market Withdrawals and Safety Alerts
	                Press Announcements
	                Warning Letters
	                Advisory Committees
	                En Español

					Products
            Food
							Drugs
							Medical Devices
							Radiation-Emitting Products
							Vaccines, Blood, and Biologics
							Animal and Veterinary
							Cosmetics
							Tobacco ProductsTopics
            About FDA
							Combination Products
							Regulatory Information
							Safety
							Emergency Preparedness
							International Programs
							News and Events
							Training and Continuing Education
							Inspections and Compliance
							Science and ResearchInformation For
            Consumers
	            Patients
	            Industry
	            Health Professionals
	            Federal, State and Local Officials 
 In this section:

                HIV Treatment

HIV Treatment

                        HIV Treatment Information for Adults
          HIV Treatment Information for Children
          HIV Treatment Information for Pregnant Patients Home
          Drugs
          Drug Safety and Availability
          Information by Drug Class
          Human Immunodeficiency Virus (HIV)
          HIV Treatment
          HIV Treatment Information for ChildrenHIV Treatment HIV Treatment Information for Children
  
  					Get Drug Information for Pediatric Patients
	
    Share
    Post
    Linkedin

    Email
    Print*Please refer to the most current drug label for pediatric patients with renal impairment.

For body weight- and BSA-based dosing in pediatric patients, do not exceed the recommended adult daily dose.

**General Considerations:**

Before prescribing tablets/capsules, pediatric patients should be assessed for the ability to swallow.


Filter by

Drug Class Combination ProductsCYP3A InhibitorEntry Inhibitors - CCR5 co-receptor antagonistFusion InhibitorsIntegrase InhibitorsNucleoside Reverse Transcriptase InhibitorsProtease Inhibitors

**Clear Filter | Search**





Recommended Pediatric Dosing of Antiretrovirals.

	Pediatric dosages by age and/or weight for the treatment of HIV-1 infection.
	Brand
			Generic
			Drug Class
			Dosage Form
			Weight
			Age
			Pediatric Dosing
			Visit Drugs@FDA to viewAtripla*
			efavirenz 600 mg
			emtricitabine 200 mg
			tenofovir disoproxil fumarate 300 mg
			Combination Products
			Oral Tablet
			≥40 kg
			
			One tablet once daily on an empty stomach, preferably at bedtime
			Atripla LabelBiktarvy*
			bictegravir 50 mg
			emtricitabine 200 mg
			tenofovir alafenamide 25 mg
			Combination Products
			Oral Tablet
			≥ 25 kg
			
			One tablet once daily with or without food
			Biktarvy LabelCimduo*
			lamivudine 300 mg
			tenofovir disoproxil fumarate 300 mg
			Combination Products
			Oral Tablet
			≥ 35 kg
			
			One tablet once daily with or without food
			Cimduo LabelCombivir*
			zidovudine 300 mg
			lamivudine 150 mg
			Combination Products
			Oral Tablet
			≥ 30 kg
			
			One tablet twice daily
			Combivir LabelComplera*
			emtricitabine 200 mg
			rilpivirine 25 mg
			tenofovir disoproxil fumarate 300 mg
			Combination Products
			Oral Tablet
			≥ 35 kg
			
			One tablet once daily with food
			Complera LabelDelstrigo
			doravirine 100 mg
			lamivudine 300 mg
			tenofovir disoproxil fumarate 300 mg
			Combination Products
			Oral Tablet
			
			
			None available
			Delstrigo LabelDescovy*
			emtricitabine 200 mg
			tenofovir alafenamide 25 mg
			Combination Products
			Oral Tablet
			Dosing for ≥ 25 kg
			No dosing available for < 35 kg when coadministered with an HIV-1 protease inhibitor with ritonavir or cobicistat
			
			One tablet once daily with or without food
			Descovy LabelDovato
			dolutegravir 50 mg
			lamivudine 300 mg
			Combination Products
			Oral Tablet
			
			
			None available
			Dovato LabelEpzicom*
			abacavir 600 mg
			lamivudine 300 mg
			Combination Products
			Oral Tablet
			≥ 25 kg
			
			One tablet once daily with or without food
			Epzicom LabelEvotaz
			atazanavir 300 mg
			cobicistat 150 mg
			Combination Products
			Oral Tablet
			≥ 35 kg
			
			For treatment-naive and -experienced patients weighing ≥ 35 kg: One tablet once daily with food
			Evotaz LabelGenvoya*
			elvitegravir 150 mg
			cobicistat 150 mg
			tenofovir alafenamide 10 mg
			emtricitabine 200 mg
			Combination Products
			Oral Tablet
			≥ 25 kg
			
			One tablet once daily with food
			Genvoya LabelJuluca
			dolutegravir 50 mg
			rilpivirine 25 mg
			Combination Products
			Oral Tablet
			
			
			None available
			Juluca LabelKaletra
			lopinavir 100 mg and ritonavir 25 mg  
			lopinavir 200 mg and ritonavir 50 mg
			Combination Products
			Oral Tablet
			
			≥ 14 days
			Once daily dosing regimen not recommended. Twice daily dose is based on body weight or body surface area. Please see Full Prescribing Information for dosing regimen.
			Kaletra LabelKaletra
			lopinavir 80 mg/mL and ritonavir 20 mg/mL
			Combination Products
			Oral Solution
			
			≥ 14 days
			Once daily dosing regimen not recommended. Twice daily dose is based on body weight or body surface area. Must be given with food. Please see Full Prescribing Information for dosing regimen.
			Kaletra LabelOdefsey*
			emtricitabine 200 mg
			rilpivirine 25 mg
			tenofovir alafenamide 25 mg
			Combination Products
			Oral Tablet
			≥ 35 kg
			
			One tablet once daily with a meal
			Odefsey LabelPrezcobix
			darunavir 800 mg
			cobicistat 150 mg
			Combination Products
			Oral Tablet
			≥ 40 kg
			
			For treatment-naïve and treatment-experienced patients weighing ≥ 40 kg with no darunavir resistance associated substitutions: one tablet once daily with food
			Prezcobix LabelStribild*
			elvitegravir 150 mg
			cobicistat 150 mg
			emtricitabine 200 mg
			tenofovir disoproxil fumarate 300 mg
			Combination Products
			Oral Tablet
			≥ 35 kg
			≥ 12 years
			One tablet once daily with food
			Stribild LabelSymfi*
			efavirenz 600 mg
			lamivudine 300 mg
			tenofovir disoproxil fumarate 300 mg
			Combination Products
			Oral Tablet
			≥ 40 kg
			
			One tablet once daily on an empty stomach, preferably at bedtime
			Symfi LabelSymfi Lo*
			efavirenz 400 mg
			lamivudine 300 mg
			tenofovir disoproxil fumarate 300 mg
			Combination Products
			Oral Tablet
			≥ 35 kg
			
			One tablet once daily on an empty stomach, preferably at bedtime
			Symfi Lo LabelSymtuza
			darunavir 800 mg
			cobicistat 150 mg
			emtricitabine 200 mg
			tenofovir alafenamide 10 mg
			Combination Products
			Oral Tablet
			
			
			None available
			Symtuza LabelTriumeq*
			dolutegravir 50 mg
			abacavir 600 mg
			lamivudine 300 mg
			Combination Products
			Oral Tablet
			≥ 40 kg
			
			One tablet once daily with or without food
			Triumeq LabelTrizivir*
			abacavir 300 mg
			lamivudine 150 mg
			zidovudine 300 mg
			Combination Products
			Oral Tablet
			≥ 40 kg
			
			One tablet twice daily with or without food
			Trizivir LabelTruvada
			emtricitabine (FTC), tenofovir disoproxil fumarate (TDF):
			100 mg FTC/150 mg TDF                              
			133 mg FTC/200 mg TDF                             
			167 mg FTC/250 mg TDF
			Combination Products
			Oral Tablet
			Between 17 kg and < 35 kg
			
			One tablet daily based on body weight. Please see Full Prescribing Information for dosing
			Truvada LabelTruvada
			emtricitabine (FTC), tenofovir disoproxil fumarate (TDF):
			200 FTC/300 mg TDF
			Combination Products
			Oral Tablet
			≥ 35 kg
			
			One tablet once daily with or without food
			Truvada LabelEmtriva
			emtricitabine 200 mg
			Nucleoside Reverse Transcriptase Inhibitors
			Oral Capsule
			≥ 33 kg who can swallow an intact capsule
			3 months through 17 years of age
			One capsule once daily with or without food
			Emtriva LabelEmtriva
			emtricitabine 10 mg/mL
			Nucleoside Reverse Transcriptase Inhibitors
			Oral Solution
			
			
			0-3 months: 3 mg per kg given once daily                   
			3 months through 17 years of age: 6 mg per kg up to a maximum of 240 mg (24 mL) once daily                                          May be taken without with or without food
			Emtriva LabelEpivir*
			lamivudine 150 mg, 300 mg
			Nucleoside Reverse Transcriptase Inhibitors
			Oral Tablet
			≥ 14 kg
			≥ 3 months
			Dosing based on body weight using a 150 mg scored tablet or alternatively a non-scored 300 mg tablet with or without food. Please see Full Prescribing Information for dosing regimen.
			Epivir LabelEpivir*
			lamivudine 10 mg/mL
			Nucleoside Reverse Transcriptase Inhibitors
			Oral Solution
			
			≥ 3 months
			5 mg per kg twice daily or 10 mg per kg once daily (up to a maximum of 300 mg daily) with or without food
			Epivir LabelRetrovir*
			zidovudine 100 mg
			Nucleoside Reverse Transcriptase Inhibitors
			Oral Capsule
			≥ 4 kg
			4 weeks to less than 18 years
			Dosage should be calculated based on body weight or BSA not to exceed adult dose. Please see Full Prescribing Information for dosing regimen.
			Retrovir LabelRetrovir*
			zidovudine 10 mg/mL
			Nucleoside Reverse Transcriptase Inhibitors
			Oral Syrup
			≥ 4 kg
			4 weeks to less than 18 years
			Dosage should be calculated based on body weight or BSA not to exceed adult dose. Please see Full Prescribing Information for dosing regimen.
			Retrovir LabelRetrovir*
			zidovudine 20-ml single-use vial (10 mg/mL)
			Nucleoside Reverse Transcriptase Inhibitors
			Intravenous Injection
			
			Neonates unable to receive oral dosing may be administered RETROVIR intravenously.
			Start neonatal dosing within 12 hours after birth and continue through 6 weeks of age.
			1.5mg/kg infused over 30 minutes every 6 hours. Total dose is 6mg/kg/day. Please see Full Prescribing Information for oral dosing.
			Retrovir LabelTemixys*
			lamivudine 300 mg
			tenofovir disoproxil fumarate 300 mg
			Nucleoside Reverse Transcriptase Inhibitors
			Oral Tablet
			≥ 35 kg
			
			One tablet once daily with or without food
			Temixys LabelVidex*
			didanosine 2 g, 4 g
			Nucleoside Reverse Transcriptase Inhibitors
			Oral Powder for Solution
			
			≥ 2 weeks to 18 years old
			Dosing is based on body weight and administered on an empty stomach at least 30 minutes before or 2 hours after eating. Please see Full Prescribing Information for details
			Videx LabelVidex EC*
			didanosine delayed-release capsule 125 mg, 200 mg, 250 mg, 400 mg
			Nucleoside Reverse Transcriptase Inhibitors
			Oral Capsule
			≥ 20 kg
			≥ 6 years to 18 years
			Dosing is based on body weight and administered on an empty stomach once daily. Please see Full Prescribing Information for dosing.
			Videx EC LabelViread*
			tenofovir disoproxil fumarate 300 mg
			Nucleoside Reverse Transcriptase Inhibitors
			Oral Tablet
			≥ 35 kg
			≥ 2 years
			For patients weighing at least 35 kg, one tablet (300 mg) taken orally once daily without regard to food
			Viread LabelViread*
			tenofovir disoproxil fumarate 150 mg, 200 mg, 250 mg
			Nucleoside Reverse Transcriptase Inhibitors
			Oral Tablet
			≥ 17 kg - < 35 kg
			≥ 2 years
			For patients weighing at least 17 kg who can swallow an intact tablet, one tablet (150 mg, 200 mg, 250 mg, or 300 mg based on body weight) once daily taken orally without regard to food. Please see Full Prescribing Information for details
			Viread LabelViread*
			tenofovir disoproxil fumarate 40 mg per gram of powder
			Nucleoside Reverse Transcriptase Inhibitors
			Oral Powder
			≥ 10 kg
			≥ 2 years
			For patients weighing at least 10 kg and unable to swallow a tablet, 8 mg per kg  oral powder (up to a maximum of 300 mg) taken once daily with soft food. Please see Full Prescribing Information for details
			Viread LabelZerit
			stavudine 15 mg, 20 mg, 30 mg, 40 mg
			Nucleoside Reverse Transcriptase Inhibitors
			Oral Capsule
			
			Birth to 13 days old
			0.5 mg/kg given every 12 hours
			Zerit LabelZerit
			stavudine 15 mg, 20 mg, 30 mg, 40 mg
			Nucleoside Reverse Transcriptase Inhibitors
			Oral Solution
			< 30 kg
			≥ 14 days
			1 mg/kg given every 12 hours
			Zerit LabelZerit
			stavudine 15 mg, 20 mg, 30 mg, 40 mg
			Nucleoside Reverse Transcriptase Inhibitors
			Oral Capsule
			≥ 30 kg
			
			Use the recommended adult dosage
			Zerit LabelZiagen
			abacavir 300 mg
			Nucleoside Reverse Transcriptase Inhibitors
			Oral Tablet
			≥ 14 kg
			≥ 3 months
			Dosing based on body weight given once or twice daily. Please see Full Prescribing Information for details
			Ziagen LabelZiagen
			abacavir 20 mg/ mL
			Nucleoside Reverse Transcriptase Inhibitors
			Oral Solution
			
			≥ 3 months
			8 mg per kg orally twice daily or 16 mg per kg orally once-daily (up to a maximum of 600 mg daily)
			Ziagen LabelEdurant
			rilpivirine 25 mg
			Nonnucleoside Reverse Transcriptase Inhibitors
			Oral Tablet
			≥ 35 kg
			≥ 12 years
			One tablet once daily with a meal
			Edurant LabelIntelence
			etravirine 25, 100, 200 mg
			Nonnucleoside Reverse Transcriptase Inhibitors
			Oral Tablet
			≥ 10 kg
			≥ 2 years to less than 18 years
			Dosing based on body weight not exceeding the recommended adult dosage and taken following a meal. Please see Full Prescribing Information for dosing.
			Intelence LabelPifeltro
			doravirine 100 mg
			Nonnucleoside Reverse Transcriptase Inhibitors
			Oral Tablet
			
			
			None available
			Pifeltro LabelRescriptor
			delavirdine 200 mg
			Nonnucleoside Reverse Transcriptase Inhibitors
			Oral Tablet
			
			≥ 16 years
			None available for < 16 years. If ≥16 years, use adult dosing
			Rescriptor LabelSustiva
			efavirenz 600 mg
			Nonnucleoside Reverse Transcriptase Inhibitors
			Oral Tablet
			≥ 3.5 kg
			≥ 3 months
			Dosing based on body weight. Please see Full Prescribing Information for dosing.
			Sustiva LabelSustiva
			efavirenz 50, 200 mg
			Nonnucleoside Reverse Transcriptase Inhibitors
			Oral Capsule
			≥ 3.5 kg
			≥ 3 months
			Dosing based on body weight. Please see Full Prescribing Information for dosing.
			Sustiva LabelViramune*
			nevirapine 200 mg
			Nonnucleoside Reverse Transcriptase Inhibitors
			Oral Tablet
			
			≥ 15 days
			Dosing based on BSA once daily for 14 days followed by twice daily thereafter. Total daily dose should not exceed 400 mg for any patient. Please see Full Prescribing Information for details.
			Viramune LabelViramune*
			nevirapine 50 mg/ 5mL
			Nonnucleoside Reverse Transcriptase Inhibitors
			Oral Suspension
			
			≥ 15 days
			Dosing based on BSA once daily for 14 days followed by twice daily thereafter. Total daily dose should not exceed 400 mg for any patient. Please see Full Prescribing Information for details.
			Viramune LabelViramune XR*
			nevirapine extended-release 400 mg
			Nonnucleoside Reverse Transcriptase Inhibitors
			Oral Tablet
			
			≥ 6 years to less than 18 years
			Dosing based on BSA and must initiate therapy with immediate-release VIRAMUNE (tablets or oral suspension), at a dose not to exceed 200 mg per day, administered once daily for the first 14 days, followed by VIRAMUNE XR 400 mg once daily. Please see Full Prescribing Information for dosing details.
			Viramune XR LabelAptivus
			tipranavir 250 mg
			Protease Inhibitors
			Oral Capsule
			
			≥ 2 years to less than 18 years
			Dosing based on body weight and BSA twice daily, and can be taken with or without meals. Not to exceed the recommended adult dose. Please see Full Prescribing Information for dosing details.
			Aptivus LabelAptivus
			tipranavir 100 mg/ mL
			Protease Inhibitors
			Oral Solution
			
			≥ 2 years to less than 18 years
			Dosing based on body weight and BSA twice daily, and can be taken with or without meals. Not to exceed the recommended adult dose. Please see Full Prescribing Information for dosing details.
			Aptivus LabelCrixivan
			indinavir 200 mg, 400 mg
			Protease Inhibitors
			Oral Capsule
			
			
			None available
			Crixivan LabelInvirase
			saquinavir mesylate 500 mg
			Protease Inhibitors
			Oral Tablet
			
			≥ 16 years of age
			See adult dosing recommendations. Please see Full Prescribing Information for dosing details.
			Invirase LabelLexiva
			fosamprenavir 700 mg
			Protease Inhibitors
			Oral Tablet
			
			≥ 4 weeks to less than 18 years
			Dosing based on body weight and should not exceed the recommended adult dose. Take tablets with or without food. Please see Full Prescribing Information for dosing details.
			Lexiva LabelLexiva
			fosamprenavir 50 mg/ml
			Protease Inhibitors
			Oral Suspension
			
			≥ 4 weeks to less than 18 years
			Dosing based on body weight and should not exceed the recommended adult dose. Take oral suspension with food. Please see Full Prescribing Information for dosing details.
			Lexiva LabelNorvir
			ritonavir 100 mg
			Protease Inhibitors
			Oral Tablet
			
			≥ 1 month
			The recommended twice daily dose with meals for children greater than one month of age is based on BSA and should not exceed 600 mg twice daily with meals. Please see Full Prescribing Information for details regarding dosing
			Norvir LabelNorvir
			ritonavir 100 mg/packet
			Protease Inhibitors
			Oral Powder
			
			≥ 1 month
			The recommended dosing is increments of 100 mg. NORVIR powder should not be used for doses less than 100 mg or for incremental doses between 100 mg intervals. Please see Full Prescribing Information for details regarding dosing for oral solution and oral powder
			Norvir LabelNorvir
			ritonavir 80 mg/mL
			Protease Inhibitors
			Oral Solution
			
			≥ 1 month
			NORVIR oral solution should not be administered to neonates before a postmenstrual age (first day of the mother’s last menstrual period to birth plus the time elapsed after birth) of 44 weeks has been attained. The recommended dose is based on BSA . Please see Full Prescribing Information for details regarding dosing for oral solution and oral powder
			Norvir LabelPrezista
			darunavir 75 mg, 150 mg, 600 mg, 800 mg
			Protease Inhibitors
			Oral Tablet
			≥ 10 kg
			≥ 3 years to less than 18 years
			Dosing based on body weight and should not exceed the adult dose and should be taken with ritonavir and with food. Please see Full Prescribing Information for details regarding dosing in oral tablet.
			Prezista LabelPrezista
			darunavir 100 mg/mL
			Protease Inhibitors
			Oral Suspension
			≥ 10 kg
			≥ 3 years to less than 18 years
			Dosing based on body weight and should not exceed the adult dose and should be taken with ritonavir and with food. Please see Full Prescribing Information for details regarding dosing in  oral suspension.
			Prezista LabelReyataz*
			atazanavir sulfate 150 mg, 200 mg, 300 mg
			Protease Inhibitors
			Oral Capsule
			≥ 15 kg
			≥ 6 years to less than 18 years
			Capsule dosage is based on body weight not to exceed the adult dose and must be taken with food. Please see Full Prescribing Information.
			Reyataz LabelReyataz*
			atazanavir sulfate 50 mg/packet
			Protease Inhibitors
			Oral Powder
			≥ 5 kg
			≥ 3 months
			Oral powder dosage must be taken with ritonavir and food and should not be used in pediatric patients who weigh less than 5 kg. Dosage is based on body weight, please see Full Prescribing Information.
			Reyataz LabelViracept
			nelfinavir mesylate 250 mg, 625 mg
			Protease Inhibitors
			Oral Tablet
			≥ 10 kg
			2 to less than 13 years
			• Recommended dosing based on body weight of 45 to 55 mg/kg twice daily or 25 to 35 mg/kg three times daily with a meal.
			• Please refer to the Full Prescribing Information for specific dosing guidelines based on age and body weight.
			• Patients ≥ 13 years should refer to adult recommended dosing.
			Viracept LabelFuzeon
			enfuvirtide lyophilized powder 108 mg/vial
			Fusion Inhibitors
			Subcutaneous Injection
			≥ 11 kg
			
			Recommended dosing is 2 mg per kg twice daily up to a maximum dose of 90 mg twice daily injected subcutaneously into the upper arm, anterior thigh or abdomen. Please see Full Prescribing Information for dosing recommendations based on body weight.
			Fuzeon LabelSelzentry*
			maraviroc 25 mg, 75 mg, 150 mg, 300 mg
			Entry Inhibitors - CCR5 co-receptor antagonist
			Oral Tablet
			≥ 10 kg
			≥ 2 years
			Dosing is based on body weight  and concomitant medications administered twice daily with
			or without food and should not exceed the recommended adult dose. Please see the Full Prescribing Information for dosing details.
			Selzentry LabelSelzentry*
			maraviroc 20 mg/mL
			Entry Inhibitors - CCR5 co-receptor antagonist
			Oral Solution
			≥ 10 kg
			≥ 2 years
			Dosing is based on body weight  and concomitant medications administered twice daily with
			or without food and should not exceed the recommended adult dose. Please see the Full Prescribing Information for dosing details.
			Selzentry LabelIsentress
			raltegravir film-coated 400 mg
			Integrase Inhibitors
			Oral Tablet
			≥ 2 kg
			
			If weighing at least 40 kg, and either treatment-naïve patients or patients who are virologically suppressed on an initial regimen of ISENTRESS 400 mg twice daily:
			• 1200 mg (2 x 600 mg) film-coated tablet orally, once daily or
			• 400 mg film-coated tablet orally, twice daily or
			• 300 mg chewable tablets, twice daily
			If weighing at least 25 kg: One 400 mg film-coated tablet orally, twice daily. If unable to swallow a tablet, consider the chewable tablet.
			If at least 4 weeks of age and weighing at least 3 kg to less than 25 kg: Dosing based on body weight. For patients weighing between 11 and 20 kg, either the chewable tablet or the formulation for oral suspension can be used.                                
			For neonates (birth to 4 weeks [28 days] of age) weighing at least 2 kg: dosing based on body weight for oral suspension.  Please see the Full Prescribing Information for details on dosing.
			Isentress LabelIsentress HD
			raltegravir HD film-coated 600 mg
			Integrase Inhibitors
			Oral Tablet
			≥ 40 kg
			
			If weighing at least 40 kg, and either treatment-naïve patients or patients who are virologically suppressed on an initial regimen of ISENTRESS 400 mg twice daily:
			• 1200 mg (2 x 600 mg) film-coated tablet orally, once daily or
			• 400 mg film-coated tablet orally, twice daily or
			• 300 mg chewable tablets, twice daily
			If weighing at least 25 kg: One 400 mg film-coated tablet orally, twice daily. If unable to swallow a tablet, consider the chewable tablet.
			If at least 4 weeks of age and weighing at least 3 kg to less than 25 kg: Dosing based on body weight. For patients weighing between 11 and 20 kg, either the chewable tablet or the formulation for oral suspension can be used.                                
			For neonates (birth to 4 weeks [28 days] of age) weighing at least 2 kg: dosing based on body weight for oral suspension.  Please see the Full Prescribing Information for details on dosing.
			Isentress LabelIsentress
			raltegravir 25, 100 mg
			Integrase Inhibitors
			Oral Chewable Tablet
			≥ 2 kg
			
			If weighing at least 40 kg, and either treatment-naïve patients or patients who are virologically suppressed on an initial regimen of ISENTRESS 400 mg twice daily:
			• 1200 mg (2 x 600 mg) film-coated tablet orally, once daily or
			• 400 mg film-coated tablet orally, twice daily or
			• 300 mg chewable tablets, twice daily
			If weighing at least 25 kg: One 400 mg film-coated tablet orally, twice daily. If unable to swallow a tablet, consider the chewable tablet.
			If at least 4 weeks of age and weighing at least 3 kg to less than 25 kg: Dosing based on body weight. For patients weighing between 11 and 20 kg, either the chewable tablet or the formulation for oral suspension can be used.                                
			For neonates (birth to 4 weeks [28 days] of age) weighing at least 2 kg: dosing based on body weight for oral suspension.  Please see the Full Prescribing Information for details on dosing.
			Isentress LabelIsentress
			raltegravir 100 mg/packet
			Integrase Inhibitors
			Oral Suspension
			≥ 2 kg
			
			If weighing at least 40 kg, and either treatment-naïve patients or
			patients who are virologically suppressed on an initial regimen of ISENTRESS 400 mg twice daily:
			• 1200 mg (2 x 600 mg) film-coated tablet orally, once daily or
			• 400 mg film-coated tablet orally, twice daily or
			• 300 mg chewable tablets, twice daily
			If weighing at least 25 kg: One 400 mg film-coated tablet orally, twice daily. If unable to swallow a tablet, consider the chewable tablet.
			If at least 4 weeks of age and weighing at least 3 kg to less than 25 kg: Dosing based on body weight. For patients weighing between 11 and 20 kg, either the chewable tablet or the formulation for oral suspension can be used.
			                                
			For neonates (birth to 4 weeks [28 days] of age) weighing at least 2 kg: dosing based on body weight for oral suspension.  Please see the Full Prescribing Information for details on dosing.
			Isentress Label InformationTivicay*
			dolutegravir 10 mg, 25mg, 50 mg
			Integrase Inhibitors
			Oral Tablet
			≥ 30 kg
			
			Dosing based on body weight once to two times daily with or without food. Please see Full Prescribing Information for dosing details for treatment-naïve or treatment-experienced INSTI-naïve patients weighing at least 30kg.
			Tivicay LabelTybost*
			cobicistat 150 mg
			CYP3A Inhibitor
			Oral Tablet
			≥ 35 kg
			
			150 mg orally once daily with atazanavir 300 mg orally once daily given with food. TYBOST must be given in combination with atazanavir. Please see Full Prescribing Information for dosing details.
			Tybost LabelTybost*
			cobicistat 150 mg
			CYP3A Inhibitor
			Oral Tablet
			≥ 40 kg
			
			150 mg orally once daily and darunavir 800 mg orally once daily given with food. TYBOST must be given in combination with darunavir. Please see Full Prescribing Information for dosing details.
			Tybost Label

                                                                                  Content current as of:
      08/07/2020
              
              
Regulated Product(s)
		 Drugs
			  			     			  						              
			
			
			
			
						  HIV/AIDS Drugs
			  			     			  			     Generic DrugsHealth Topic(s)
			  HIV/AIDSLaw(s) & Regulation(s)
			  President's Emergency Plan for AIDS Relief (PEPFAR)HIV Treatment

          
                        HIV Treatment Information for Adults
          HIV Treatment Information for Children
          HIV Treatment Information for Pregnant Patients
 
 Footer Links
    FDA Archive
          About FDA
          Accessibility
      Visitor Information
          Website Policies / Privacy
          No FEAR Act
          Vulnerability Disclosure Policy
      FOIA
          HHS.gov
          USA.gov
    Contact FDA
      Follow FDA on Facebook
      Follow FDA on X
      Follow FDA on Instagram
      Follow FDA on LinkedIn
      View FDA videos on YouTube
      Subscribe to FDA RSS feeds
    FDA Homepage
    Contact Number
      1-888-INFO-FDA (1-888-463-6332) Back toTop